October 18, 2023
ThinkEquity Conference October 19, 2023
Immunophotonics CEO Lu Alleruzzo will be participating at the ThinkEquity Conference in Mandarin Oriental, New York on October 19th. Check...
Read More
October 16, 2023
Bio Investor Forum, October 17-18, 2023
Immunophotonics Co-founder, CIO, and President Tomas Hode, PhD will be attending one of the most significant investor conferences in San...
Read More
October 10, 2023
Immunophotonics Announces First Patient Dosed in the United States under its Investigational New Drug (IND) Application
Immunophotonics CEO Lu Alleruzzo announced, along with Dr. Robert CG Martin II, M.D, PhD, PACS, who serves as the Principal...
Read More
September 26, 2023
Immunophotonics’ Fast-Track Grant from NIH’s National Cancer institute was granted approval to transition from Phase I to Phase II
Immunophotonics was recently granted approval by the NIH’s National Cancer Institute to transition from Phase I to Phase II Fast-track...
Read More
September 25, 2023
Immunophotonics Announces 1st Patient Dosed in Multinational Clinical trial in France
Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in a multinational clinical trial in France at...
Read More
September 14, 2023
RESI Boston 2023 – September 18th
Immunophotonics Co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Boston attending the RESI Boston...
Read More
September 13, 2023
CIRSE 2023 September 9 – 13, 2023
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be at Booth F18 at the CIRSE...
Read More
July 17, 2023
Immunophotonics Announces 1st Patient Treated in Germany
Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in Germany at SLK Kliniken Heilbronn GmbH. The...
Read More
June 1, 2023
Immunophotonics Announces 1st Patient Dosed in Multinational Clinical Trial in the United Kingdom
Immunophotonics, Inc. has announced the recruitment and the dosing of its first patient in a multinational clinical trial in the...
Read More
June 1, 2023
SACHS Forum and ASCO Annual Meeting in Chicago June 2 – 6, 2023
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Chicago at the SACHS 9th...
Read More